4 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
Follow Baodong Qin: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC NSCLC Stage IV, EGFR T790M-negative | Unknown | Baodong Qin | 100 | 2019-09-01 | 2019-10-07 | |
| Effect of Chemotherapy on PD-L1 in NSCLC PD-L1 group - Chemotherapy, Immunotherapy | Unknown | Baodong Qin | 30 | 2018-09-01 | 2018-10-10 | |
| Effect of Chemotherapy on TMB in NSCLC Next-Genernation Sequence - Chemotherapy Effect, Immunotherapy | Unknown | Baodong Qin | 30 | 2018-09-01 | 2018-09-25 | |
| Efficacy and Safety of Precision Therapy in Refractory Tumor Gefitinib, Erlotinib, Afatinib - Rare Tumor, Refractory Tumor | Phase 2 | Unknown | Baodong Qin | 300 | 2017-01-01 | 2022-03-04 |
Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1)
Afatinib (1) · Erlotinib Hydrochloride (1) · Everolimus (1) · Gefitinib (1) · Trastuzumab (1) · Vemurafenib (1) · cabozantinib (1) · dabrafenib (1) · olaparib (1) · oxazolidine (1) · palbociclib (1)
China (4)